Ocugen has announced the publication of positive results from its phase 1 GARDian1 trial of OCU410ST, a gene therapy for ...

The global DNA methylation market size was valued at US$ 1.9 Bn in 2025 and is projected to reach US$ 7.7 Bn by 2036, growing ...

Fortress Biotech has announced that its subsidiary, Cyprium Therapeutics, received US FDA approval for Zycubo for the ...

A research team at the Medical University of Vienna has discovered a new approach to treating a particularly frequent and ...

SHELTON, CONNECTICUT / ACCESS Newswire / January 13, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a ...

The FDA has approved Zycubo (copper histidinate) injection as the first and only treatment of Menkes disease in pediatric patients.

A research team at the Medical University of Vienna has discovered a new approach to treating a particularly frequent and difficult-to-treat form of lung cancer.

Fund is collected in the name of public interest. In practice, a substantial portion of the money ends up financing private ...

PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles ...

The "Canada Next-Generation Sequencing (NGS) Market - A Canada and Regional Analysis: Focus on Application, Technology, Offering, End User, and Regional Analysis - Analysis and Forecast, 2025-2035" ...

Shares of Beam Therapeutics BEAM were up 22.3% on Monday after the company outlined strategic priorities and some expected ...

The result is one molecule that can be both a checkpoint degrader and a cancer vaccine ( Nature 2026, DOI: 10.1038/s41586-025 ...